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Congestive heart failure is an important cause of morbidity
and mortality in western countries . In the United States up
to 2% of the adult population (-2.3 million persons) have
heart failure, and the overall 5-year mortality rate is approx-
imately 50% (1) . Until recently, diuretic agents and digoxin
formed the basis of conventional treatment for this condi-
tion. However, the effects of both of these treatments on
disease progression and survival are not known reliably .
More recently, angiotensin-converting enzyme inhibitors
have been shown to reduce morbidity and mortality in a
broad spectrum of patients with heart failure (23) or asymp-
tomatic left ventricular dysfunction (4,5) .
However, despite such treatments and the attendant
improvements in prognosis, the outlook for such patients
remains poor. In the First Cooperative North Scandinavian
Enalapril Survival Study (CONSENSUS I) (2), -one third
of the patients with severe heart failure assigned treatment
with enalapril died within 1 year, and in the Studies of Left
Ventricular Dysfunction (SOLVD) (3), a similar proportion
of patients with moderate heart failure died within 3 years .
Thus, there remains a need for treatments that will further
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improve the prognosis . One group of drugs that may provide
further benefit is the beta-adrenergic antagonists . The ratio-
nale for the use of beta-blockers in heart failure derives from
the following:first, studies of neurohormonal alterations and
their prognostic importance in heart failure ; second, ran-
domized trials of the effects of beta-blockers on left ventric-
ular function and exercise capacity in patients with heart
ailure ; and third, randomized trials of 1he effects of beta-
blockers on mortality in patients with myocardial infarction
and evidence of heart failure . Evidence from each of these
sources is discussed in this review .
Neurobormonal Alterations in Heart Failure
With the onset of heart failure, compensatory changes
occur in the sympathetic and parasympathetic nervous sys-
tems, in the renin-angiotensin-aldosterone system and in
plasma arginine vasopressin . These changes are partially
offset by increases in vasodilator prostaglandin, atrial
natriuretic peptide and brain natriuretic peptide . Eventually,
however, the net result is excessive vasoconstriction, vol-
ume expansion and worsening symptoms and signs of
congestive heart failure. Studies have demonstrated that
atrial natriuretic peptide and renin (6) and norepinephrine
(7,8) are each independent predictors of mortality . Agents
that block these activated neurohormonal systems therefore
have potential value as therapeutic agents in heart failure .
The benefits of blockade of the renin-angiotensin-
aldosterone system with angiotensin-converting enzyme in-
hibitors are well established . There may also be benefits of
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blockade of the sympathetic nervous system with beta-
blockers. Such benefits may be complementary to those
provided by angiotensin-converting enzyme inhibitors .
Sympathetic Nervous System
Plasma norepinephrine levels. The plasma concentration
of norepinephrine provides an index of sympathetic tone .
Several studies have shown that plasma norepinephrine
levels are increased in heart failure, indicating sympathetic
overactivity (7,9, 10) . As well as a predictor of survival (7,8),
the level of circulating norepinephrine is directly propor-
tional to the degree of left ventricular dysfunction (9) .
Indeed, measurements of norepinephrine may provide a
better prognostic guide than hemodynamic measurements,
such as cardiac index, stroke work index or pulmonary
capillary wedge pressure (7) .
Recent data from a substudy of the SOLVD trial (11) have
demonstrated that sympathetic activation occurs before the
development of clinical heart failure and is present in pa-
tients with asymptomatic left ventricular dysfunction . Sym-
pathetic activation is therefore not solely a consequence of
clinical heart failure . Overactivity of the sympathetic ner-
vous system may result from long-term changes in stroke
volume, cardiac output and mean arterial pressure that result
in deactivation of arterial baroreceptors that play an impor-
tant role in negative feedback control of the sympathetic
nervous system (12,13) . Prolonged, excessive activation of
the sympathetic nervous system has many potential adverse
effects, including direct toxic effects on the myocardium
(14), arrhythmogencsis (15), decreased coronary blood flow
and tissue anoxia from vasoconstriction (12) .
Cardiac norepinephrine stores. Despite increased plasma
concentrations of norepinephrine in heart failure, the myo-
cardium is depleted of norepinephrine (16,17) . This is due, at
least partly, to a profound decrease in reuptake of norepi-
nephrine (18) . The reuptake mechanism is a major determi-
nant of both the concentration of norepinephrine within the
synaptic cleft and the stores of norepinephrine in the neuron .
In addition to abnormal reuptake of norepinephrine, it has
been suggested that abnormalities occur in the synthesis of
norepinephrine within the neuron (19,20), although this has
not been a consistent finding (21) . The exact mechanism of
the depleted norepinephrine stores is still uncertain and may
depend on the underlying cause of the heart failure .
Effect of beta-blockade on plasma norepinephrine levels .
A recent randomized trial of the effects of bucindolol in
patients with idiopathic dilated cardiomyopathy (22) has
demonstrated a 50% reduction in plasma norepinephrine
levels in bucindolol-treated patients after 3 months . These
findings and those from nonrandomized studies (23,24)
suggest that beta-blockade may reduce circulating norepi-
nephrine levels both by reducing spillover to the plasma
from the synaptic cleft and by increasing clearance of
norepinephrine .
Beta-blockers are also able to block directly the toxic
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effects of catecholamines, as demonstrated in vivo by rever-
sal of the cardiomyopathy associated with pheochromocy-
toma (25) .
-adrenergic receptors . In addition to the increase in
plasma norepinephrine, other alterations occur in the adren-
ergic pathway, including changes in the beta-receptor den-
sity and function, guanine nucleotide regulatory proteins (or
G proteins) and c ,  clic adenosine monophosphate (AMP)
levels .
In the normal myocardium there is a predominance of the
beta,-subgroup of receptors . In heart failure there is a
decrease in the total beta-receptor density that is related to
the degree of heart failure (26) . This is due to a selective
reduction, or "downregulaiion," in the beta,-receptor den-
sity of -60% to 70% (27) . It has also been demonstrated in
patients with severe heart failure that downregulation of
the beta,-receptors is accompanied by a reduction in the
corresponding beta,-receptor messenger ribonucleic acid
(mPNA) (28), No such changes were seen in beta
2
-receptor
density or in beta,-receptor mRNA. These findings suggest
that the beta,-receptor downregulation is at least partly the
consequence of a reduction in the synthesis of the beta,-
receptors. However, it is also possible that the beta,-
receptor downregulation reflects an increase in receptor
degradation (29), although this remains to be shown in failing
human hearts .
The absolute density of the beta 2-receptor is unchanged
in heart failure, although the ratio of beta 2-receptors to
beta,-receptors is increased, and their functional activity is
reduced (30) . Several different mechanisms are involved in
this receptor "uncoupling" (31). One important pathway
involves initial phosphorylation of the agonist-occupied ac-
tive receptors by beta-adrenergic receptor kinase (32) . Sub-
sequently, an inhibitory protein, beta-arrestin (33), binds to
the phosphorylated receptor, resulting in uncoupling of the
beta-receptor and the G proteins (see later) and a reduction
in their function .
Alterations in the beta-receptors may be a response to
increased sympathetic activity or a result of progressive
heart muscle damage, or both (34) . Thus, it is uncertain
whether these alterations in beta-receptors are specific to
heart failure or merely reflect the marked sympathetic acti-
vation that occurs in this condition (31) . Downregulation of
the beta-receptors does not occur uniformly throughout the
myocardium and is more marked in the subendocardial
myocytes, suggesting that it is not simply related to the
increase in sympathetic activity (35) .
Effect of beta-blovkade on beta-receptor density. Two
nonrandomized studies of metoprolol (36,37) in patients with
idiopathic dilated cardiomyopathy have suggested that long-
term treatment with this agent increases beta-receptor den-
sity . The patients in these series also showed significant
hemodynamic improvement
. A recent randomized, placebo-
controlled trial with metoprolol has also demonstrated a
significant increase in beta-receptor density after 6 months of
treatment (38) . However, in that study there was no
sign!
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icant change in ejection fraction in metoprolol-treated pa-
tients compared with control subjects (39) .
Although the
increase in betas-receptor density seen after treatment with
beta-blockers appears to occur within days (40), the clinical
benefits of beta-blockade have typically been observed after
longer-term therapy (>2 months) (22,41-55), and thus it is
unlikely that this improvement is explained simply by beta-
receptor upregulation alone .
The underlying cause of the heart failure may influence
the changes seen in the beta-receptor complex . Bristow et al .
(56) have recently shown that compared with idiopathic
dilated cardiomyopathy, ischemic cardiomyopathy has less
total beta-receptor downregulation and greater uncoupling of
left ventricular beta2-receptors and right ventricular beta,-
receptors. These differences may explain why beta-blockade
has been reported to produce greater effects on left ventric-
ular function in idiopathic dilated cardiomyopathy than in
ischemic cardiomyopathy (48) .
G proteins . The guanine nucleotide regulatory proteins
(or G proteins) exist on the inner surface of the cell mem-
brane and provide the link between the beta-receptor and
adenylyl cyclase . Some G proteins stimulate adenylyl cy-
clase (G, proteins), and others are inhibitory (G i proteins) .
They share a common structure, each being composed of
alpha-, beta- and gamma-subunits, with the alpha-subunit
thought to be responsible for regulating the effector systems
(57,58) . There are alterations in these proteins in the failing
human myocardium, including an increase of as much as a
third in the Go protein (59,60) and a reduction in the G,
protein (61). These alterations in the G proteins, as well as
the receptor modifications previously mentioned, probably
account for the "uncoupling" of the beta,-receptors seen
in heart failure (34) . The G, proteins interact directly with
the catalytic unit of adenylyl cyclase, and it appears that
the activity of this subunit may be decreased in heart failure
(62) .
of therapeutic interventions on the G proteins .
Treatment of patients with heart failure with the angiotensin-
converting enzyme inhibitors captopril and lisinopril has
been shown (63) to result in significant increases in lympho-
cyte G, protein levels and beta-receptor density . These
changes may be associated with the reduced sympathetic
nervous activity that has been reported after angiotensin-
converting enzyme inhibition (64,65) or occur indirectly as a
result of the overall hemodynamic improvement that occurs
with such therapy .
Little is known of the effects of beta-blockade on the
levels of r proteins in patients with heart failure . If beta-
blockade has beneficial effects on the G protein levels, then
this may have important implications for ventricular contrac-
tility
. It is possible that the increased response to dobu-
tamine stimulation that has been documented after beta-
blockade (40) may be due to alterations in the G protein
levels as well as in beta-receptor density and function .
Previous Clinical ri Is of eta®l keys i
Heart Failure
Traditionally, beta-blockers have been considered con-
traindicated in heart failure because of their acute negative
inotropic effect . The first report of their application in heart
failure (66) described patients with severe idiopathic dilated
cardiomyopathy who appeared to have a favorable clinical
response to beta-blockade with metoprolol. A subsequent
report (67) suggested that in comparison with historical
control subjects, survival was prolonged with the beta-
blocker treatment. A further report of patients with idio-
pathic dilated cardiomyopathy indicated improvement in
hemodynamic status and symptoms with beta-blockade (68)
and significant hemodynamic deterioration on withdrawal
(69) .
The initial observations of the effects of beta-blockers
were all derived from nonrandomized studies, but these have
since been followed by a number of randomized, placebo-
controlled trials in patients with heart failure of different
types. Table I lists the 16 randomized trials of beta-blockade
in 906 patients with heart failure that have beer, reported to
date (22,41-55). These trials predominantly included patients
with idiopathic dilated cardiomyopathy, although some have
also included patients with ischemic cardiomyopathy
(42,46-48,51,53-55) . Most but not all of these studies re-
ported a lessening of symptoms and a reduction in New York
Heart Association functional class with long-term treatment
(>2 months) (22,43-46,48-51,53) . The two studies that did
not report improvement had a very short treatment period
(t month) and a small number of patients (41,42) .
Hem ynamic effects of beta-blockade in heart failure . In
patients with heart failure, long-term beta-blockade has been
shown (22,42,44-48,50-55) to result in significant hemody-
namic improvement with increased left ventricular stroke
work index, left ventricular ejection fraction and decreased
pulmonary capillary wedge pressure . In those studies that
measured ejection fraction, the weighted mean absolute
increase in the beta-blocker group relative to the control
group was 5.4% (Table 1) . The randomized trials have
principally involved patients with idiopathic dilated cardio-
myopathy. In these patients the weighted mean increase in
the beta-blocker group relative to the control group was
5.2%. Further study is required of the effects of beta-
blockers in patients with heart failure due to ischemic heart
disease because there is some evidence that the effects may
be different in this group (48) . Different responses may also
be observed between the different classes of beta-blockers,
which may be clinically relevant .
The mechanisms of hemodynamic improvement with
long-term beta-blockade in heart failure are unclear . Short-
term intravenous beta-blockade has been demonstrated to
adversely affect left ventricular systolic function (70) . How-
ever, long-term oral therapy is well tolerated and can result
in significant hemodynamic improvement. Most studies in-
vestigating the possible mechanisms of improvement have
JACC Vol . 23, No. 3
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Table 1. Randomized, Controlled Trials of Beta-Adrenergic
*Crossover design . 'Dose titration study (significant change in ejection fraction at higher doses only) . flncluded some of the patients from Ref 22 . Weighted
by the number of patients in each trial . AEF = mean difference in ejection traction percent (calculated as mean change during active treatment - mean change
during control ; NA = data not available .
not been randomized and have involved a small number of
patients; perhaps, as a consequence, their results are con-
flicting .
Eichhorn et al . (71), in a nonrandomized study of the
effects of 3 months of treatment with bucindolol (an agent
with both beta-blocking and mild vasodilating properties) in
patients with heart failure, demonstrated an increase in left
ventricular ejection fraction that was related to reduction in
both end-systolic and end-diastolic volumes . The decrease in
end-systolic volume and increase in ejection fraction oc-
curred despite a decrease in preload and an increase in
afterload, suggesting improvement in myocardial contractil-
ity. These changes were confirmed by improvement in the
end-systolic pressure-volume relation and peak first &riva-
tive of left ventricular pressure (dP/dt-end-diastolic volume
relation) both relatively load-independent measures of con-
tractility . Despite this improvement in contractility and
mechanical work, there was no increase in myocardial
oxygen consumption .
The finding of improved contractility after long-term
beta-blockad has also been demonstrated (55) in a placebo-
controlled study of nebivolol, a beta,-selective antagonist
with vasodilating properties, in patients with dilated cardio-
myopathy . That study demonstrated no significant change in
wall stress, suggesting that the significant increase in ejec-
tion fraction observed was due to improved contractility
rather than to ventricular unloading .
In addition to improvement in rest hemodynamic vari-
ables after beta-blockade, improvement has also been dem-
onstrated (23,24) in cardiac, stroke volume and stroke work
indexes and pulmonary capillary wedge pressure with exer-
cise. In association with this improvement there was no
increase in myocardial oxygen consumption, suggesting in-
locking Agents in Congestive Heart Failure
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creased myocardial work load without higher metabolic
costs .
Few data are available with regard to the effects of
beta-blockade on diastolic function in heart failure . Improve-
ment has been demonstrated in isovolumetric relaxation,
with no change in chamber stiffness after treatment with
bucindolol (71) . Improved diastolic function may be an
important component of the response to beta-blockade and
requires further investigation .
Effects of beta-blockade on exeicise tolerance in heart
failure . The findings related to exercise capacity in the trials
conducted to date have been conflicting (Table 1) . Although
some studies (44-46,49,50) have reported statistically signif-
icant improvement in total exercise duration with beta-
blockade, others (22,41-43,48,55) have not . Long-term beta-
blockade can attenuate maximal oxygen consumption (72) ;
consequently, maximal exercise tolerance testing may not be
the most appropriate method for assessing improvement in
functional capacity . In a recent randomized trial of the
effects of the vasodilating beta-blocker carvedilol (73), sub-
maximal exercise time (determined by stressing patients at a
work load fixed at 85% of their baseline maximal oxygen
consumption) was significantly increased in the beta-blocker
group compared with the placebo group, whereas maximal
exercise time was not changed . A similar study (51) has
recently shown a significant increase in the distance tra-
versed during a 6-min walk test in the beta-blocker-treated
group compared with findings in the placebo-treated group .
This method of assessing submaximal performance is often
preferred by patients and may better reflect 'imitations of
their regular daily physical activity than does maximal
exercise testing (74) .
Study
No. of P15
Beta-Blocker Follow-Up (mo)
AEF
Exercise Tolerance
(Treadmill
lkram and Fitzpatrick W
Currie et al . (42)~
15
10
Acehutolol
Metoprolol
I
1
NA
+3 .0
Decrease
No change
Anderson et al . (43) 50 Metoprolol
19
NA No change
Engelmeier et al
. (44)* 40 Metoprolol
12 +2 .0
Increase
Leung a al. 04
12 Labetolol 2
NA
Increase
Pollock et al . (46)
19 Bucindolol 3
0.0
Increase
Gilbert et al (22) 24
Bucindolol 3
+8 .0
No change
Bristow et al . (47)t 141
Bucindolol 3
+4 .1 NA
Woodley et al . (48)t 49
Bucindolol 3
+0 .5 No change
Paolisso et al . (49)* 10 Metoprolol
3
NA Increase
MDC Trial Study Group (50) 380 Metoprolol
12-18
+6 .0 Increase
Krum et al . (51) 32 Carveddol 3 .5
+5 .5
NA
Metre et al. (52) 20 Carvedilol
6 NA
NA
Olsen et al . (53) 54 Carvedilol 4
+10.0
NA
Bennett et al . (54) 50 Metoprolol 6
+5 .0 NA
Wisenbaugh et al . (55) 21 NebivoU 3
+8 .0
No change
906
+5A§
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Effects of beta-blockade on survival in bout failure. The
recently reported Metoprolol in Dilated Cardiomyopathy
study (50) is the largest study to date of the effects of
beta-blockade in patients with heart failure . Three hundred
eighty-three patients were iandomized to receive either
metoprolol or placebo and were followed for 12 to 18
months. There were significant improvements in hemody-
namic variables and symptoms, as well as fewer hospital
readmissions in the beta-blocker-treated group . There was
no statistically significant effect on total mortality, but fewer
metoprolol-treated patients were placed on the transplant
list . A larger study with several thousand patients would be
required for the assessment of plausible survival benefit .
Sumnuiry.
These data indicating improvement in hemo-
dynamic variables, clinical symptoms and, possibly, exer-
cise performance are not yet sufficient to justify the wide-
spread use of beta-blockers in all patients with heart failure .
The experience with other agents in heart failure, such as
milrinone (75), which produce favorable short-term hemo-
dynamic and clinical effects but actually increase mortality
in the long term, indicates the importance of mortality data
in the consideration of general treatment recommendations .
However, some mortality data from the numerous trials of
beta-blockers after myocardial infarction are relevant and
reassuring .
Trials of Beta-lockers After
Myocardial Infarction
The benefits of beta-blockers in patients with myocardial
infarction have been demonstrated in a large number of
randomized controlled trials (76). Overall these trials have
shown that long-term therapy confers a rednction of -20 176
in mortality (76) . Nevertheless, concern still exists with
regard to the safety u : beta-blockers in patients with im-
paired left ventricular function after myocardial infarction .
This cencern relates primarily to the short-term negative
inotropic effects of beta-blockers (70) and their potential to
precipitate or worsen heart failure . However, in at least two
nonrandomized studies, beta-blocker use was associated
with a lower mortality rate in patients with various indexes
of heart failure or left ventricular dysfunction (77,78) .
Stronger evidence that beta-blockers may confer survival
benefit in patients with heart failure was provided by the
Beta-Blocker Heart Attack Trial (BRAT) (79) . In that trial,
710 of the 3,837 patients randomized had a history of heart
failurz
. Among these patients with heart failure there were
-25% te ,;-. ,er deaths in those assigned to receive propranolol
than in those roceiving placebo
. This difference, although of
borderline statistical significance (p = 0
.07), appeared to be
of similar magnitude to the highly significant difference in
mortality observed in the much larger group of patients
without a history of heart failure
. The lower mortality in
patients with heart failure assigned propranolol primarily
JACC Vol
. 23, No. 3
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resulted from a reduction in sudden death of -one-hall
(p = 0.02).
In the Beta-Blocker Pooling Project (80), results from
nine trials involving a total of 13,679 patients were combined
to allow greater power for the detection of treatment effects
among subgroups of randomized patients . Although the
subgroup with chronic heart failure comprised BHAT pa-
tients almost entirely, there was additional information pro-
vided on the effects of treatment in a total of 3,519 patients
with previous heart failure (as indicated by pulmonary
edema, cardiogenic shock, persistent hypotension, basilar
rates or other symptoms or signs of heart failure at the time
of the acute infarction) . Among these patients there was a
significant reduction in total mortality of -25% (p = 0 .004) in
those assigned treatment with a beta-blocker . Similarly, in
the 2,625 patients with systolic blood pressure < 110 mm Hg,
there was a significant reduction in total mortality of -50%
(p = 0 .0002) in those treated with a beta-blocker (a similar
result was observed in those with diastolic blood pressure
<70 mm Hg). Finally, of the 957 patients receiving digitalis
before randomization, mortality was reduced by -33%
(p = 0.01) in those assigned to receive a beta-blocker .
Thus, it is apparent that some patients with heart failure
or left ventricular dysfunction after acute myocardial infarc-
tion may benefit from beta-blocker therapy . However, it is
uncertain how generalizable these results from the postin-
farction trials are, given that the groups chosen for study
were highly selected .
Potential Benefits of Beta-Blockers in the
Context of Current Management
The CONSENSUS 1 (2) and SOLVD (3) trials have
clearly demonstrated that angiotensin-converting enzyme
inhibitors can reduce mortality in patients with heart failure .
This benefit appears to be primarily the consequence of
reduced mortality from progressive heart failure, although
the results of one study suggested some reduction in sudden
death (81). The possibility that beta-blockade may provide
further survival benefit by reducing the risk of sudden death
is particularly relevant because sudden death still accounts
for between one-third and one-half of all deaths in patients
with heart failure .
The exact mechanism of action of beta-blockers in the
prevention of sudden death after myocardial infarction is
uncertain (12). A reduction in ventricular arrhythmias has
been postulated from a retrospective analysis of subgroups
of patients in BHAT (83). Those with arrhythmias had the
most pronounced effect from beta-blockade, with mortality
being halved in the treatment group . After myocardial in-
farction, metoprolol has been reported to have a pronounced
effect on prevention of ventricular fibrillation (84) . Beta-
blockers have an effect on the fibrillation threshold rather
than on ventricular ectopic beats, and this effect may confer
protection from sudden death (85) . However, the failure of
JACC Vol . 23, No . 3
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class IC antiarrhythmic agents to reduce mortality after
myocardial infarction in the Cardiac Arrhythmia Suppres-
sion Trial (CAST) (86) and of amiodarone to reduce mortal-
ity in patients with heart failure (87) has suggested that
simple suppression of arrhythmias is not the answer to
reducing sudden death in this high risk situation .
Several cardioprotective actions of beta-blockers have
been proposed, including antiarrhythmic effects (88), de-
creased myocardial oxygen demand (69), antithrombotic
effect (89) and prevention of plaque rupture (90) . Beta-
blockers may prevent ischemia by decreasing heart rate,
blood pressure and myocardial contractility (82) . However,
in heart failure their effects may be more complex, and
myocardial oxygen demand may remain unchanged (71). A
20% reduction in the incidence of nonfatal reinfarction was
observed in the overview of the long-term trials of beta-
blockade by Yusuf et al . (76), suggesting a role in reducing
ischemia . A reduction in the rate of recurrent myocardial
infarction has also recently been demonstrated with angiu •
tensin-converting enzyme inhibition in the Survival and
Ventricular Enlargement (SAVE) (4) and SOLVE) trials (91),
although the mechanisms of benefit are probably different
from those of beta-blockers . Angiotensin-converting enzyme
inhibitors w ty have unique vascular protective and antiath-
erosclerotic effects (92), thus extending the rationale for
complementary benefits from combination treatment with
beta-blockade and angiotensin-converting enzyme inhibition
after myocardial infarction and in heart failure .
Conclusions
Congestive heart failure is a common problem, and mor-
tality remains high despite recent improvements in treat-
ment. Complex neurohormonal alterations occur in heart
failure that are deleterious in the long term and adversely
affect survival. Angiotensin-converting enzyme inhibition
has been shown to have beneficial effects on hemodynamic
status, symptoms and survival . Beta-adrenergic antagonists
are also able to modulate the neirohormonal activation of
heart failure. Clinical trials of beta-blockers in ischemic and
idiopathic dilated cardiomyopathy have shown that they
improve hemodynamic status and do not worsen symptoms .
After myocardial infarction, beta-blockers reduce the inci-
dence of sudden death, particularly in patients with heart
failure . Further studies are required to determine whether
beta-blockade can further reduce mortality is Incart failure
and thereby provide a useful addition to existing therapy .
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